J&J Reports $16.76B in 3Q Innovative Medicine Sales
Johnson & Johnson reported worldwide Innovative Medicine sales of $16.76 billion in the third quarter.
Story updates
10:20:22 AM UTC
SquawkNews
Johnson & Johnson: 3Q Innovative Medicine Operational Sales Grew 7.9%, With Divestitures Negatively Affecting Growth by 10 Basis Points >JNJ
10:20:23 AM UTC
SquawkNews
Johnson & Johnson: 3Q Innovative Medicine Operational Sales Growth Driven Primarily by Tremfya, Darzalex, Carvykti, Tecvayli, Rybrevant/Lazcluze, Erleada, Caplyta and Spravato >JNJ
10:20:40 AM UTC
SquawkNews
Johnson & Johnson reported Q3 2026 results and raised its full-year 2026 guidance. Innovative Medicine operational sales grew 7.9% and MedTech grew 2.5%, excluding currency.Material DetailsContext by AI AnalystThis is a mid-cycle confirmation of J&J’s pivot to growth in Innovative Medicine with ste…